{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:26:55Z","timestamp":1790245615246,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacadv.2025.102356","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T19:21:55Z","timestamp":1766604115000},"page":"102356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["Patient-Centered Outcomes in Heart Failure Pharmacotherapy"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-8025","authenticated-orcid":false,"given":"Kazuhiko","family":"Kido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Guglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacadv.2025.102356_bib1","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5603\/cj.92243","article-title":"Quality of life in heart failure: new data, new drugs and devices","volume":"31","author":"Major","year":"2024","journal-title":"Cardiol J"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis","volume":"23","author":"Turgeon","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/ehjcvp\/pvad088","article-title":"Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Oriecuia","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1838","article-title":"Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials","volume":"23","author":"von Haehling","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102356_bib6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102356_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.jacadv.2025.102356_bib8","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.jacadv.2025.102356_bib9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/jama.2025.3833","article-title":"Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial","volume":"333","author":"Anker","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102356_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jchf.2015.10.015","article-title":"Utility of patient-reported outcome instruments in heart failure","volume":"4","author":"Kelkar","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102356_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/0002-9149(93)90582-W","article-title":"Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo","volume":"71","author":"Rector","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.102356_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2025.102356_bib14","author":"Rohatgi"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102356_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacadv.2025.102356_bib17","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102356_bib18","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.jacadv.2025.102356_bib19","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/eurheartj\/ehab411","article-title":"The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial","volume":"42","author":"Martens","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib20","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2019-0156","article-title":"Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency","volume":"6","author":"Dhoot","year":"2020","journal-title":"Future Sci OA"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"issue":"10369","key":"10.1016\/j.jacadv.2025.102356_bib22","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102356_bib23","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","article-title":"Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group","volume":"92","year":"1995","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(01)00146-5","article-title":"Effect of metoprolol CR\/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial","volume":"3","author":"Gullestad","year":"2001","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.CIR.101.4.378","article-title":"Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1067\/mhj.2002.121269","article-title":"Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging","volume":"143","author":"Dubach","year":"2002","journal-title":"Am Heart J"},{"issue":"6 Pt 1","key":"10.1016\/j.jacadv.2025.102356_bib28","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0002-8703(99)70083-9","article-title":"Metoprolol CR\/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction","volume":"138","author":"Goldstein","year":"1999","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102356_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurjhf\/hfp066","article-title":"Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/01.CIR.92.6.1499","article-title":"Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure","volume":"92","author":"Krum","year":"1995","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102356_bib31","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/0735-1097(94)90174-0","article-title":"Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy","volume":"24","author":"Metra","year":"1994","journal-title":"J Am Coll Cardiol"},{"issue":"3 Pt 1","key":"10.1016\/j.jacadv.2025.102356_bib32","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0002-8703(99)70148-1","article-title":"Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol","volume":"138","author":"Guazzi","year":"1999","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib33","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0735-1097(95)00012-S","article-title":"Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study","volume":"25","author":"Olsen","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jacadv.2025.102356_bib34","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102356_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102356_bib36","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102356_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102356_bib39","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO(2)): a randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib40","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib42","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jacadv.2025.102356_bib44","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib45","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102417","article-title":"Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial","volume":"16","author":"Requena-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102356_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102356_bib48","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ejhf.2738","article-title":"Health-related quality of life outcomes in PARAGON-HF","volume":"24","author":"Chandra","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102356_bib49","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10.1016\/j.jacadv.2025.102356_bib50","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib51","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.102356_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2021.05.005","article-title":"Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study","volume":"239","author":"Dos Santos","year":"2021","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102356_bib54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102356_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","article-title":"Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102356_bib56","series-title":"Efficacy and Mechanism Evaluation. Spironolactone to Improve Exercise Tolerance in People with Permanent Atrial Fibrillation and Preserved Ejection Fraction: The IMPRESS-AF RCT","author":"Shantsila","year":"2020"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102356_bib57","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib58","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/jgs.14940","article-title":"Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction","volume":"65","author":"Upadhya","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib59","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jcmg.2017.10.007","article-title":"Association of active and passive components of LV diastolic filling with exercise intolerance in heart failure with preserved ejection fraction: mechanistic insights from spironolactone response","volume":"12","author":"Kosmala","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib60","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102356_bib61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102356_bib62","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib64","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10.1016\/j.jacadv.2025.102356_bib65","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1570161114666160505143003","article-title":"Impact of ivabradine on health-related quality of life of patients with ischaemic chronic heart failure","volume":"14","author":"Sallam","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib67","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1074248410370326","article-title":"Impact of ''Off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure","volume":"15","author":"Sarullo","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib69","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"10266","key":"10.1016\/j.jacadv.2025.102356_bib71","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib72","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ehf2.12250","article-title":"Single-dose intravenous iron in southeast Asian heart failure patients: a pilot randomized placebo-controlled study (PRACTICE-ASIA-HF)","volume":"5","author":"Yeo","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib73","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.94.11.2800","article-title":"Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group","volume":"94","author":"Colucci","year":"1996","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102356_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1071-9164(97)90013-0","article-title":"Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group","volume":"3","author":"Cohn","year":"1997","journal-title":"J Card Fail"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib75","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102356_bib76","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102356_bib77","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1388-9842(00)00078-7","article-title":"MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing","volume":"2","author":"Genth-Zotz","year":"2000","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ejheart.2003.11.025","article-title":"Betablockers in heart failure: carvedilol safety assessment (CASA 2-trial)","volume":"6","author":"Rickli","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib80","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102356_bib81","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jacc.2024.06.036","article-title":"Effects of sotagliflozin on health status in patients with worsening heart failure: results from SOLOIST-WHF","volume":"84","author":"Bhatt","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib82","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.12669\/pjms.39.6.7525","article-title":"The effect of dapagliflozin on renal functions in hospitalized patients with acute heart failure","volume":"39","author":"Gilani","year":"2023","journal-title":"Pak J Med Sci"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102356_bib83","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cjco.2020.04.007","article-title":"Canadian real-world experience of using sacubitril\/valsartan in patients with heart failure with reduced ejection fraction: insight from the PARASAIL study","volume":"2","author":"Haddad","year":"2020","journal-title":"CJC Open"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchf.2020.09.012","article-title":"Improvement of health status following initiation of sacubitril\/valsartan in heart failure and reduced ejection fraction","volume":"9","author":"Pi\u00f1a","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib88","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1067\/mhj.2002.120775","article-title":"Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal efficacy and SUrvival study)","volume":"143","author":"Spertus","year":"2002","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1751-7133.2009.00056.x","article-title":"Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure","volume":"15","author":"Daniel","year":"2009","journal-title":"Congest Heart Fail"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102356_bib91","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5603\/CJ.a2014.0057","article-title":"I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: impact on the exercise tolerance and quality of life","volume":"22","author":"Abdel-Salam","year":"2015","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102356_bib92","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1054\/jcaf.2003.7","article-title":"The effect of digoxin on the quality of life in patients with heart failure","volume":"9","author":"Lader","year":"2003","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102356_bib93","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0002-9149(88)90947-2","article-title":"A controlled trial of digoxin in congestive heart failure","volume":"61","author":"Guyatt","year":"1988","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102356_bib94","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(10)80194-9","article-title":"Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial","volume":"17","author":"Fleg","year":"1991","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacadv.2025.102356_bib95","first-page":"436","article-title":"Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. The CADS study group","volume":"18","author":"Just","year":"1993","journal-title":"Herz"},{"issue":"6 Suppl","key":"10.1016\/j.jacadv.2025.102356_bib96","first-page":"Vi56","article-title":"Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Ziesche","year":"1993","journal-title":"Circulation"},{"issue":"6 Suppl","key":"10.1016\/j.jacadv.2025.102356_bib97","first-page":"Vi71","article-title":"Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Rector","year":"1993","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jacadv.2025.102356_bib98","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102356_bib99","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1249\/MSS.0000000000001513","article-title":"Effect of beta-blocker treatment on V\u02d9O2peak in patients with heart failure","volume":"50","author":"Montero","year":"2018","journal-title":"Med Sci Sports Exerc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:06:33Z","timestamp":1771358793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25007860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772963X25007860"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102356","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Centered Outcomes in Heart Failure Pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102356"}}